Genflow Biosciences Plc announced the international publication of its Patent Cooperation Treaty application WO 2026/062177 A1, covering variants of sirtuin 6 intended for the prevention and treatment of muscular diseases, with a specific focus on frailty syndrome and sarcopenia.
The published application describes compositions and methods that include nucleic acids, polypeptides, vectors and pharmaceutical formulations aimed at muscle-mass loss and altered muscle endocrine function.
The company claims the PCT publication expands its intellectual property estate beyond longevity and metabolic uses and preserves its ability to seek patent protection across multiple jurisdictions.
Genflow identifies its lead program, GF-1002, as a gene therapy delivering a centenarian variant of SIRT6 and notes that a proof-of-concept clinical trial in aged dogs began in March 2025.
Founded in 2020 with headquarters in the UK and R&D facilities in Belgium, Genflow positions the filing as part of a broader strategy to strengthen its platform and enable development and partnering opportunities.
